GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » EV-to-EBIT

Quoin Pharmaceuticals (Quoin Pharmaceuticals) EV-to-EBIT : 1.36 (As of Jun. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quoin Pharmaceuticals's Enterprise Value is $-11.86 Mil. Quoin Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.70 Mil. Therefore, Quoin Pharmaceuticals's EV-to-EBIT for today is 1.36.

The historical rank and industry rank for Quoin Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

QNRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.56   Med: 0   Max: 1.91
Current: 1.36

During the past 5 years, the highest EV-to-EBIT of Quoin Pharmaceuticals was 1.91. The lowest was -10.56. And the median was 0.00.

QNRX's EV-to-EBIT is ranked better than
63.29% of 425 companies
in the Biotechnology industry
Industry Median: 9.78 vs QNRX: 1.36

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Quoin Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $-11.08 Mil. Quoin Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.70 Mil. Quoin Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 78.45%.


Quoin Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Quoin Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals EV-to-EBIT Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -0.38 0.69 0.67

Quoin Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.02 1.10 0.67 1.27

Competitive Comparison of Quoin Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Quoin Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quoin Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's EV-to-EBIT falls into.



Quoin Pharmaceuticals EV-to-EBIT Calculation

Quoin Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-11.864/-8.695
=1.36

Quoin Pharmaceuticals's current Enterprise Value is $-11.86 Mil.
Quoin Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quoin Pharmaceuticals  (NAS:QNRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Quoin Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-8.695/-11.0838285
=78.45 %

Quoin Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $-11.08 Mil.
Quoin Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quoin Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper director PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell director C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn officer: Chief Financial Officer AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter director, officer: Chief Operating Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers director, officer: Chief Executive Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines